Vijaya Diagnostic Q2 FY27 Revenue Surges 26.7% YoY to ₹255.4 Crore
Vijaya Diagnostic Centre reported Q2 FY27 revenue growth of 26.7% YoY to ₹255.4 crore. EBITDA grew 37.8% to ₹112.7 crore, and PAT increased 37.4% to ₹59.5 crore. The company plans to commission 3 hubs and 7 spokes in H2 FY27. It also acquired Arya Wellness Centre in Guwahati.
The significant revenue growth, improved margins, expansion plans, and strategic acquisition indicate a material positive impact on the company's financial health and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with operational highlights and expansion plans, indicating a positive financial performance and outlook.
Vijaya Diagnostic Centre Limited announced its financial results for the quarter ended September 30, 2026. The company reported a strong consolidated revenue growth of 26.7% year-on-year, reaching ₹2,553.9 million (₹255.4 crore) for Q2 FY27, compared to ₹2,015.6 million (₹201.6 crore) in Q2 FY26. EBITDA increased by 37.8% to ₹1,127.5 million (₹112.7 crore), with the EBITDA margin improving by 355 basis points to 44.1%. Profit after Tax (PAT) grew by 37.4% to ₹594.7 million (₹59.5 crore), and the PAT margin expanded by 181 basis points to 23.3%.
Operationally, the company saw a 16.5% increase in total tests conducted, reaching 4.98 million in Q2 FY27. Total footfall also rose by 14.5% to 1.37 million. The average realization per test increased by 8.8% to ₹513, and the average realization per footfall grew by 10.6% to ₹1,865.
Ms. Suprita Reddy, MD & CEO, stated that existing centers grew by approximately 20%, and newer centers are ramping up well. The company is seeing encouraging momentum in West Bengal and a meaningful turnaround in Pune. For expansion, Vijaya Diagnostic has commissioned 2 hubs and 7 spokes in FY27 and plans to commission another 3 hubs and 7 spokes in H2 FY27, followed by 3 additional hubs in Q1 FY28.
Additionally, the company entered into a Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam, marking its entry into the North-East region. This acquisition is seen as a strong platform to establish a presence in Guwahati and explore further growth opportunities in the region.
What to do with a filing like this
Vijaya Diagnostic Centre Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vijaya Diagnostic Centre Limited. Read the original for the full detail.